stoxline Quote Chart Rank Option Currency Glossary
  
enVVeno Medical Corporation (NVNO)
5.945  -0.005 (-0.08%)    07-12 14:11
Open: 5.97
High: 6.09
Volume: 40,858
  
Pre. Close: 5.95
Low: 5.86
Market Cap: 79(M)
Technical analysis
2024-07-12 2:23:32 PM
Short term     
Mid term     
Targets 6-month :  7.12 1-year :  8.32
Resists First :  6.09 Second :  7.12
Pivot price 5.29
Supports First :  4.98 Second :  4.28
MAs MA(5) :  5.57 MA(20) :  5.16
MA(100) :  5.28 MA(250) :  4.91
MACD MACD :  0.2 Signal :  0.1
%K %D K(14,3) :  95.3 D(3) :  83
RSI RSI(14): 71.4
52-week High :  6.96 Low :  2.98
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NVNO ] has closed Bollinger Bands are 33.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.11 - 6.13 6.13 - 6.15
Low: 5.77 - 5.8 5.8 - 5.83
Close: 5.91 - 5.95 5.95 - 5.99
Company Description

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Headline News

Wed, 26 Jun 2024
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation - Simply Wall St

Tue, 25 Jun 2024
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - Yahoo Finance

Fri, 21 Jun 2024
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting - Raleigh News & Observer

Wed, 08 May 2024
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update - Sacramento Bee

Wed, 24 Apr 2024
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium - Miami Herald

Wed, 06 Mar 2024
EnVVeno Medical’s VenoValve Trial Shows Promising Results - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 13 (M)
Shares Float 13 (M)
Held by Insiders 0.3 (%)
Held by Institutions 27.3 (%)
Shares Short 839 (K)
Shares Short P.Month 884 (K)
Stock Financials
EPS -1.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36.8 %
Return on Equity (ttm) -57.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -17 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -3.64
PEG Ratio 0
Price to Book value 1.88
Price to Sales 0
Price to Cash Flow -4.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android